Apogee Therapeutics Inc.
- Address
- 221 Crescent Street Building 17 Suite 102 B
Sponsor Overview
Specializations
Atopic Dermatitis
Apogee Therapeutics Inc. focuses its clinical research on atopic dermatitis, with studies centered on patients with moderate-to-severe disease. The sponsor’s trial portfolio reflects sustained interest in both symptom control and longer-term treatment outcomes in this inflammatory skin disorder.
- Moderate-to-severe atopic dermatitis
- Skin inflammation
- Dermatologic disease management
The sponsor’s active studies examine effectiveness and long-term safety in the context of chronic dermatology care, with research activity distributed across multiple international sites.
Immunology and Inflammatory Disease
The company’s research activity is concentrated in immune-mediated and inflammatory disease, specifically within the atopic dermatitis landscape. This places emphasis on therapeutic areas where immune dysregulation drives persistent skin symptoms and treatment burden.
- Immune-mediated inflammation
- Chronic inflammatory skin disease
- Therapeutic response in dermatology
Current research efforts are directed toward understanding clinical benefit in patients requiring ongoing management of chronic inflammatory disease.
Dermatology Clinical Development
Apogee Therapeutics Inc. is engaged in dermatology-focused clinical development through studies evaluating treatment performance in a real-world patient population with significant disease burden. The work is centered on outcomes relevant to routine specialist care in skin disease.
- Clinical dermatology
- Treatment effectiveness
- Patient tolerability
Its research footprint includes multiple collaborating sites across several countries, supporting clinical evaluation in diverse patient settings.
Long-term Treatment Assessment
The sponsor’s studies include attention to long-term safety and sustained therapeutic performance, reflecting interest in treatments intended for ongoing use in a chronic dermatologic condition. This area is particularly relevant for patients who need continuous disease control.
- Long-term safety
- Sustained effectiveness
- Chronic disease treatment
Research activity remains concentrated in atopic dermatitis, with all active trials currently recruiting.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of APG777 Efficacy and Safety in Moderate-to-Severe Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Multicenter Trial |  Czechia France Germany Hungary Poland Spain | Not Recruiting |
| Long-term Safety and Efficacy Evaluation of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis: An Extension Study | Czechia France Germany Hungary Poland Spain | Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 44 sites across their trial portfolio.
Therapeutic Focus
- 1.Skin and Connective Tissue Diseases2 trials247 other sponsors
Partnered Research Centres
44 centres- Address
- 1 Place Alexis Ricordeau, 44000 Nantes
- Address
- 1 Rue De Germont, Bp 96031, 76031 Rouen
- Address
- Ul. Na Zaspe 3, 80-546 Gdansk
- Address
- Ul. Przedzalniana 66, 90-338 Lodz
- Address
- Ul. Gabrieli Zapolskiej 3, 41-218 Sosnowiec
- Address
- Hindenburgdamm 30, Lichterfelde, 12203 Berlin
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Apogee Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.